MK-2206
As of the edition of 20 October 2026, MK-2206 is a small molecule: stopped in 2018; acts on AKT1, AKT2 and AKT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 43, 13 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Urinary and reproductive; Blood and lymph; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 15 | 9 | 1 | 4 |
| Phase 2 | 28 | 19 | 0 | 9 |
| All trials | 43 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2008 to now |